Citigroup Cuts Avantor (NYSE:AVTR) Price Target to $9.00

Avantor (NYSE:AVTR) had its target price lowered by Citigroup from $11.00 to $9.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Citigroup’s price objective indicates a potential upside of 11.30% from the stock’s current price.

Other equities research analysts also recently issued reports about the company. Stifel Nicolaus set a $10.00 target price on Avantor in a report on Thursday, February 12th. Robert W. Baird set a $11.00 target price on Avantor in a report on Thursday, February 12th. TD Cowen reissued a “hold” rating on shares of Avantor in a report on Thursday, February 12th. Wells Fargo & Company lowered their price target on Avantor from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Friday, February 13th. Finally, UBS Group reaffirmed a “neutral” rating and set a $10.50 price target on shares of Avantor in a report on Thursday, February 12th. Three investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $11.39.

Avantor Stock Up 3.0%

Avantor stock traded up $0.24 during mid-day trading on Thursday, hitting $8.09. The company had a trading volume of 14,637,552 shares, compared to its average volume of 11,048,509. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.70. The stock’s 50 day moving average price is $8.16 and its two-hundred day moving average price is $10.51. Avantor has a 12 month low of $7.26 and a 12 month high of $15.93. The company has a market capitalization of $5.52 billion, a PE ratio of -10.37, a price-to-earnings-growth ratio of 3.13 and a beta of 1.00.

Avantor (NYSE:AVTR) last released its earnings results on Wednesday, April 29th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.16 by $0.01. Avantor had a positive return on equity of 10.45% and a negative net margin of 8.09%.The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.55 billion. During the same period in the previous year, the company posted $0.23 earnings per share. The company’s revenue for the quarter was up .0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Avantor will post 0.79 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Sanjeev K. Mehra bought 125,000 shares of the stock in a transaction on Tuesday, March 10th. The shares were bought at an average price of $8.01 per share, with a total value of $1,001,250.00. Following the completion of the acquisition, the director owned 475,000 shares in the company, valued at $3,804,750. The trade was a 35.71% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gregory L. Summe bought 100,000 shares of the stock in a transaction on Thursday, February 12th. The stock was purchased at an average cost of $9.40 per share, for a total transaction of $940,000.00. Following the acquisition, the director owned 400,000 shares of the company’s stock, valued at $3,760,000. This trade represents a 33.33% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 275,000 shares of company stock valued at $2,399,250 over the last ninety days. 0.28% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AVTR. Royal Bank of Canada lifted its holdings in Avantor by 104.3% in the first quarter. Royal Bank of Canada now owns 203,738 shares of the company’s stock valued at $3,302,000 after acquiring an additional 104,022 shares during the period. Empowered Funds LLC lifted its holdings in Avantor by 40.3% in the first quarter. Empowered Funds LLC now owns 17,659 shares of the company’s stock valued at $286,000 after acquiring an additional 5,075 shares during the period. Cetera Investment Advisers lifted its holdings in Avantor by 40.2% in the second quarter. Cetera Investment Advisers now owns 40,289 shares of the company’s stock valued at $542,000 after acquiring an additional 11,543 shares during the period. Quantbot Technologies LP bought a new position in Avantor in the second quarter valued at about $232,000. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Avantor by 214.9% in the second quarter. Arrowstreet Capital Limited Partnership now owns 124,076 shares of the company’s stock valued at $1,670,000 after acquiring an additional 84,679 shares during the period. Institutional investors own 95.08% of the company’s stock.

Key Avantor News

Here are the key news stories impacting Avantor this week:

• Positive Sentiment: Q1 results beat consensus: adjusted EPS of $0.17 topped estimates and revenue of $1.58B slightly exceeded expectations; the company reported positive net income, $219M adjusted EBITDA and reaffirmed FY2026 guidance — supports near‑term confidence. Avantor® Reports First Quarter 2026 Results
• Positive Sentiment: Market reaction: shares jumped after the Q1 beat and management commentary on improving demand trends, indicating investor focus on recovery in end markets. Avantor shares jump 9 after Q1 earnings beat
• Neutral Sentiment: Full earnings materials and call transcript are available for details on segment trends and cost actions — useful for investors who want to dig into guidance and margin drivers. View Press Release / Slide Deck
• Neutral Sentiment: Analyst/content coverage: AVTR is featured in retail roundups of inexpensive medical stocks, which can broaden retail interest but is not a fundamental catalyst. 5 Best Medical Stocks to Buy Under $30
• Negative Sentiment: Margin pressure and volume softness: management signaled declining margins and softer volumes in parts of the business; revenue was essentially flat year‑over‑year, and GAAP EPS declined versus prior year — these factors cap near‑term profitability upside. Avantor Q1 Earnings & Revenues Beat Estimates, Margins Decline

Avantor Company Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.